Update on antiphospholipid antibodies: Clinical significance

Angela Tincani, Tamara Ziglioli, Laura Andreoli, Pierluigi Meroni

Research output: Contribution to journalArticle

Abstract

Antiphospholipid antibodies (aPL) are autoantibodies directed to phospholipid-binding proteins and classically related to thrombosis and pregnancy loss in the so-called antiphospholipid syndrome (APS). A wide spectrum of clinical manifestations have been observed in individuals with aPL. These may be asymptomatic, or they may exhibit clinical features suggesting APS, but not fulfilling the International Classification Criteria; typical APS manifestation in the absence of detectable aPL is defined as seronegative APS; microangiopathic APS may involve either one tissue only or may present with widespread thrombosis episodes accompanied by acute multi-organ failure in the catastrophic syndrome. The detection of different aPL profiles seems to increase the diagnostic specificity of the tests. The future research should focus on the development of assays that selectively identify aPL associated with increased risk of thrombosis or pregnancy complications, in order to lead to therapeutic strategies able to prevent unresolved problems associated with aPL.

Original languageEnglish
Pages (from-to)551-560
Number of pages10
JournalInternational Journal of Clinical Rheumatology
Volume4
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Thrombosis
Pregnancy Complications
Routine Diagnostic Tests
Autoantibodies
Phospholipids
Carrier Proteins
Pregnancy

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Update on antiphospholipid antibodies : Clinical significance. / Tincani, Angela; Ziglioli, Tamara; Andreoli, Laura; Meroni, Pierluigi.

In: International Journal of Clinical Rheumatology, Vol. 4, No. 5, 2009, p. 551-560.

Research output: Contribution to journalArticle

Tincani, Angela ; Ziglioli, Tamara ; Andreoli, Laura ; Meroni, Pierluigi. / Update on antiphospholipid antibodies : Clinical significance. In: International Journal of Clinical Rheumatology. 2009 ; Vol. 4, No. 5. pp. 551-560.
@article{388553531275449f95910e57bdb74267,
title = "Update on antiphospholipid antibodies: Clinical significance",
abstract = "Antiphospholipid antibodies (aPL) are autoantibodies directed to phospholipid-binding proteins and classically related to thrombosis and pregnancy loss in the so-called antiphospholipid syndrome (APS). A wide spectrum of clinical manifestations have been observed in individuals with aPL. These may be asymptomatic, or they may exhibit clinical features suggesting APS, but not fulfilling the International Classification Criteria; typical APS manifestation in the absence of detectable aPL is defined as seronegative APS; microangiopathic APS may involve either one tissue only or may present with widespread thrombosis episodes accompanied by acute multi-organ failure in the catastrophic syndrome. The detection of different aPL profiles seems to increase the diagnostic specificity of the tests. The future research should focus on the development of assays that selectively identify aPL associated with increased risk of thrombosis or pregnancy complications, in order to lead to therapeutic strategies able to prevent unresolved problems associated with aPL.",
keywords = "Antiphospholipid antibodies, Antiphospholipid syndrome, Prophylaxis, Treatment",
author = "Angela Tincani and Tamara Ziglioli and Laura Andreoli and Pierluigi Meroni",
year = "2009",
doi = "10.2217/ijr.09.38",
language = "English",
volume = "4",
pages = "551--560",
journal = "Future Rheumatology",
issn = "1758-4272",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Update on antiphospholipid antibodies

T2 - Clinical significance

AU - Tincani, Angela

AU - Ziglioli, Tamara

AU - Andreoli, Laura

AU - Meroni, Pierluigi

PY - 2009

Y1 - 2009

N2 - Antiphospholipid antibodies (aPL) are autoantibodies directed to phospholipid-binding proteins and classically related to thrombosis and pregnancy loss in the so-called antiphospholipid syndrome (APS). A wide spectrum of clinical manifestations have been observed in individuals with aPL. These may be asymptomatic, or they may exhibit clinical features suggesting APS, but not fulfilling the International Classification Criteria; typical APS manifestation in the absence of detectable aPL is defined as seronegative APS; microangiopathic APS may involve either one tissue only or may present with widespread thrombosis episodes accompanied by acute multi-organ failure in the catastrophic syndrome. The detection of different aPL profiles seems to increase the diagnostic specificity of the tests. The future research should focus on the development of assays that selectively identify aPL associated with increased risk of thrombosis or pregnancy complications, in order to lead to therapeutic strategies able to prevent unresolved problems associated with aPL.

AB - Antiphospholipid antibodies (aPL) are autoantibodies directed to phospholipid-binding proteins and classically related to thrombosis and pregnancy loss in the so-called antiphospholipid syndrome (APS). A wide spectrum of clinical manifestations have been observed in individuals with aPL. These may be asymptomatic, or they may exhibit clinical features suggesting APS, but not fulfilling the International Classification Criteria; typical APS manifestation in the absence of detectable aPL is defined as seronegative APS; microangiopathic APS may involve either one tissue only or may present with widespread thrombosis episodes accompanied by acute multi-organ failure in the catastrophic syndrome. The detection of different aPL profiles seems to increase the diagnostic specificity of the tests. The future research should focus on the development of assays that selectively identify aPL associated with increased risk of thrombosis or pregnancy complications, in order to lead to therapeutic strategies able to prevent unresolved problems associated with aPL.

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=71249116821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71249116821&partnerID=8YFLogxK

U2 - 10.2217/ijr.09.38

DO - 10.2217/ijr.09.38

M3 - Article

AN - SCOPUS:71249116821

VL - 4

SP - 551

EP - 560

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 5

ER -